Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11920202 Unbiased identification of tumor rejection mediating neoepitopes

Patent 11920202 was granted and assigned to University of Connecticut on March, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

University of Connecticut

0

Current Assignee

University of Connecticut

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Cory A Brennick0

Ion I Mandoiu0

Marmar Moussa0

Pramod K. Srivastava0

Mariam M George0

Date of Patent

March 5, 2024

0

Patent Application Number

172253740

Date Filed

April 8, 2021

0

Patent Citations

US Patent 10426824 Compositions and methods of identifying tumor specific neoantigens

0

US Patent 8140270 Methods and systems for medical sequencing analysis

0

US Patent 10055540 Neoantigen identification, manufacture, and use

0

US Patent 10155031 Individualized vaccines for cancer

0

US Patent 10501801 Identification of tumor-protective epitopes for the treatment of cancers

0

Patent Primary Examiner

0

Patent abstract

Described herein is an unbiased method of identifying tumor rejection mediating neoepitopes (TRMNs). Putative neoepitopes from a cancer cell exome sequence from a cancer patient are putative neoepitopes are unbiased by MHC binding and/or CD8T* reactivity. By plotting the putative neoepitope IC

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11920202 Unbiased identification of tumor rejection mediating neoepitopes

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool